Comparative Pharmacology
Head-to-head clinical analysis: BETA HC versus COR OTICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETA HC versus COR OTICIN.
BETA-HC vs COR-OTICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BETA-HC (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as prostaglandins and leukotrienes. It also inhibits phospholipase A2 and reduces cytokine production.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
1-2 tablets (200-400 mg) orally every 6-8 hours as needed for pain; not to exceed 6 tablets (1200 mg) per day.
1-2 drops in each affected ear twice daily for 7 days.
None Documented
None Documented
1.5 hours (beta phase); clinical context: anti-inflammatory effects persist longer than serum levels due to receptor binding and gene transcription
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Renal (approximately 75% as metabolites, <5% unchanged); fecal (approximately 15%)
Renal (60-80% unchanged), fecal/biliary (5-10%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid + Antibiotic